IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease

Huiying Gu, Yvonne Kirchhein, Timothy Zhu, Gang Zhao, Hongjun Peng, Eileen Du, Junyi Liu, James A. Mastrianni, Martin Farlow, Richard Dodel, Yansheng Du

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether IVIG could reduce amyloid plaque pathology in vivo and be used to effectively treat animals with prion diseases. In this study, we used Gerstmann-Sträussler-Scheinker (GSS)-Tg (PrP-A116V) transgenic mice to test IVIG efficacy since amyloid plaque formation played an important role in GSS pathogenesis. Here, we provided strong evidence that demonstrates how IVIG could significantly delay disease onset, elongate survival, and improve clinical phenotype in Tg (PrP-A116V) mice. Additionally, in treated animals, IVIG could markedly inhibit PrP amyloid plaque formation and attenuate neuronal apoptosis at the age of 120 days in mice. Our results indicate that IVIG may be a potential, effective therapeutic treatment for GSS and other prion diseases.

Original languageEnglish (US)
JournalMolecular Neurobiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Intravenous Immunoglobulins
Amyloid Plaques
Autoantibodies
Prion Diseases
Transgenic Mice
Alzheimer Disease
Apoptosis
Pathology
Phenotype

Keywords

  • Amyloid plaque
  • Apoptosis
  • IVIG
  • Prion

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease. / Gu, Huiying; Kirchhein, Yvonne; Zhu, Timothy; Zhao, Gang; Peng, Hongjun; Du, Eileen; Liu, Junyi; Mastrianni, James A.; Farlow, Martin; Dodel, Richard; Du, Yansheng.

In: Molecular Neurobiology, 01.01.2018.

Research output: Contribution to journalArticle

Gu, Huiying ; Kirchhein, Yvonne ; Zhu, Timothy ; Zhao, Gang ; Peng, Hongjun ; Du, Eileen ; Liu, Junyi ; Mastrianni, James A. ; Farlow, Martin ; Dodel, Richard ; Du, Yansheng. / IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease. In: Molecular Neurobiology. 2018.
@article{64b8192c920b4fca969b2f259a2aa5aa,
title = "IVIG Delays Onset in a Mouse Model of Gerstmann-Str{\"a}ussler-Scheinker Disease",
abstract = "Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether IVIG could reduce amyloid plaque pathology in vivo and be used to effectively treat animals with prion diseases. In this study, we used Gerstmann-Str{\"a}ussler-Scheinker (GSS)-Tg (PrP-A116V) transgenic mice to test IVIG efficacy since amyloid plaque formation played an important role in GSS pathogenesis. Here, we provided strong evidence that demonstrates how IVIG could significantly delay disease onset, elongate survival, and improve clinical phenotype in Tg (PrP-A116V) mice. Additionally, in treated animals, IVIG could markedly inhibit PrP amyloid plaque formation and attenuate neuronal apoptosis at the age of 120 days in mice. Our results indicate that IVIG may be a potential, effective therapeutic treatment for GSS and other prion diseases.",
keywords = "Amyloid plaque, Apoptosis, IVIG, Prion",
author = "Huiying Gu and Yvonne Kirchhein and Timothy Zhu and Gang Zhao and Hongjun Peng and Eileen Du and Junyi Liu and Mastrianni, {James A.} and Martin Farlow and Richard Dodel and Yansheng Du",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12035-018-1228-0",
language = "English (US)",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",

}

TY - JOUR

T1 - IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease

AU - Gu, Huiying

AU - Kirchhein, Yvonne

AU - Zhu, Timothy

AU - Zhao, Gang

AU - Peng, Hongjun

AU - Du, Eileen

AU - Liu, Junyi

AU - Mastrianni, James A.

AU - Farlow, Martin

AU - Dodel, Richard

AU - Du, Yansheng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether IVIG could reduce amyloid plaque pathology in vivo and be used to effectively treat animals with prion diseases. In this study, we used Gerstmann-Sträussler-Scheinker (GSS)-Tg (PrP-A116V) transgenic mice to test IVIG efficacy since amyloid plaque formation played an important role in GSS pathogenesis. Here, we provided strong evidence that demonstrates how IVIG could significantly delay disease onset, elongate survival, and improve clinical phenotype in Tg (PrP-A116V) mice. Additionally, in treated animals, IVIG could markedly inhibit PrP amyloid plaque formation and attenuate neuronal apoptosis at the age of 120 days in mice. Our results indicate that IVIG may be a potential, effective therapeutic treatment for GSS and other prion diseases.

AB - Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from IVIG. Although autoantibodies in IVIG blocked PrP fibril formation and PrP neurotoxicity in vitro, it remained unknown whether IVIG could reduce amyloid plaque pathology in vivo and be used to effectively treat animals with prion diseases. In this study, we used Gerstmann-Sträussler-Scheinker (GSS)-Tg (PrP-A116V) transgenic mice to test IVIG efficacy since amyloid plaque formation played an important role in GSS pathogenesis. Here, we provided strong evidence that demonstrates how IVIG could significantly delay disease onset, elongate survival, and improve clinical phenotype in Tg (PrP-A116V) mice. Additionally, in treated animals, IVIG could markedly inhibit PrP amyloid plaque formation and attenuate neuronal apoptosis at the age of 120 days in mice. Our results indicate that IVIG may be a potential, effective therapeutic treatment for GSS and other prion diseases.

KW - Amyloid plaque

KW - Apoptosis

KW - IVIG

KW - Prion

UR - http://www.scopus.com/inward/record.url?scp=85050275653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050275653&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1228-0

DO - 10.1007/s12035-018-1228-0

M3 - Article

C2 - 30027340

AN - SCOPUS:85050275653

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -